biote (NASDAQ:BTMD) reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets ...

Q2 2026 earnings call recap: recall impact, guidance cut, procedure volume recovery plans, supplements growth and M&A outlook—read ...

Irving-based hormone replacement therapy provider Biote goes public via a blank check company Friday, hoping a cash injection will be a springboard for accelerated growth as it aims for $166 million ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 / EINPresswire.com / — OBGYN Specialists of Columbus is helping women better understand Bioidentical Hormone Replacement Therapy, including what BioTE pellet ...

Irving-based hormone therapy firm Biote Corp. will buy back nearly $77 million in stock to settle a lawsuit filed by the company's founder. The money will go to Gary Donovitz, who founded the company ...

biote said a voluntary recall of certain bioidentical hormone pellets in January created a temporary supply disruption that cut Q1 revenue by an estimated $1.7 million, added about $1.5 million of ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ — OBGYN Specialists of Columbus is helping women better understand Bioidentical Hormone Replacement ...